

Peter C Scacheri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6046678/publications.pdf>

Version: 2024-02-01

47
papers

4,680
citations

172207

29
h-index

197535

49
g-index

52
all docs

52
docs citations

52
times ranked

10251
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions. <i>Genome Research</i> , 2011, 21, 1273-1283.	2.4	487
2	Discovery of common and rare genetic risk variants for colorectal cancer. <i>Nature Genetics</i> , 2019, 51, 76-87.	9.4	377
3	Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. <i>Genome Research</i> , 2014, 24, 1-13.	2.4	326
4	Epigenomic Enhancer Profiling Defines a Signature of Colon Cancer. <i>Science</i> , 2012, 336, 736-739.	6.0	304
5	Molecular and phenotypic aspects of <i>CHD7</i> mutation in CHARGE syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2010, 152A, 674-686.	0.7	265
6	CHD7 Targets Active Gene Enhancer Elements to Modulate ES Cell-Specific Gene Expression. <i>PLoS Genetics</i> , 2010, 6, e1001023.	1.5	213
7	Genomic distribution of CHD7 on chromatin tracks H3K4 methylation patterns. <i>Genome Research</i> , 2009, 19, 590-601.	2.4	210
8	Functional Enhancers Shape Extrachromosomal Oncogene Amplifications. <i>Cell</i> , 2019, 179, 1330-1341.e13.	13.5	206
9	Enhancer variants: evaluating functions in common disease. <i>Genome Medicine</i> , 2014, 6, 85.	3.6	195
10	ZNF143 provides sequence specificity to secure chromatin interactions at gene promoters. <i>Nature Communications</i> , 2015, 6, 6186.	5.8	173
11	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. <i>Nature</i> , 2018, 553, 101-105.	13.7	170
12	Transcription elongation factors represent in vivo cancer dependencies in glioblastoma. <i>Nature</i> , 2017, 547, 355-359.	13.7	156
13	Epigenomic Comparison Reveals Activation of "Seed" Enhancers during Transition from Naive to Primed Pluripotency. <i>Cell Stem Cell</i> , 2014, 14, 854-863.	5.2	137
14	Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. <i>Nature Medicine</i> , 2018, 24, 176-185.	15.2	126
15	Robust Hi-C Maps of Enhancer-Promoter Interactions Reveal the Function of Non-coding Genome in Neural Development and Diseases. <i>Molecular Cell</i> , 2020, 79, 521-534.e15.	4.5	110
16	Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. <i>Nature Medicine</i> , 2018, 24, 1469-1480.	15.2	98
17	Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. <i>Nature Communications</i> , 2017, 8, 14400.	5.8	93
18	CHD7 functions in the nucleolus as a positive regulator of ribosomal RNA biogenesis. <i>Human Molecular Genetics</i> , 2010, 19, 3491-3501.	1.4	91

#	ARTICLE	IF	CITATIONS
19	Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma. <i>Journal of Experimental Medicine</i> , 2019, 216, 1071-1090.	4.2	89
20	[14] Statistics for ChIP-chip and DNase Hypersensitivity Experiments on NimbleGen Arrays. <i>Methods in Enzymology</i> , 2006, 411, 270-282.	0.4	83
21	The Chromatin Fingerprint of Gene Enhancer Elements. <i>Journal of Biological Chemistry</i> , 2012, 287, 30888-30896.	1.6	77
22	Modeling disease risk through analysis of physical interactions between genetic variants within chromatin regulatory circuitry. <i>Nature Genetics</i> , 2016, 48, 1313-1320.	9.4	57
23	Mutations in the noncoding genome. <i>Current Opinion in Pediatrics</i> , 2015, 27, 659-664.	1.0	52
24	Enhancers: bridging the gap between gene control and human disease. <i>Human Molecular Genetics</i> , 2018, 27, R219-R227.	1.4	51
25	Mutations in the <i>CHD7</i> Gene: The Experience of a Commercial Laboratory. <i>Genetic Testing and Molecular Biomarkers</i> , 2010, 14, 881-891.	0.3	46
26	Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer. <i>Human Genetics</i> , 2019, 138, 307-326.	1.8	44
27	Genetic architectures of proximal and distal colorectal cancer are partly distinct. <i>Gut</i> , 2021, 70, 1325-1334.	6.1	44
28	Upregulation of Glucose-Regulated Protein 78 in Metastatic Cancer Cells Is Necessary for Lung Metastasis Progression. <i>Neoplasia</i> , 2016, 18, 699-710.	2.3	41
29	Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer. <i>Cancer Research</i> , 2019, 79, 4599-4611.	0.4	39
30	Cell Type-Specific Intralocus Interactions Reveal Oligodendrocyte Mechanisms in MS. <i>Cell</i> , 2020, 181, 382-395.e21.	13.5	39
31	Knockdown of <i>fbx10/kdm2bb</i> rescues <i>chd7</i> morphant phenotype in a zebrafish model of CHARGE syndrome. <i>Developmental Biology</i> , 2013, 382, 57-69.	0.9	34
32	Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma. <i>Journal of Clinical Investigation</i> , 2019, 129, 4377-4392.	3.9	34
33	Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer. <i>Oncotarget</i> , 2016, 7, 53230-53244.	0.8	30
34	CHD7 represses the retinoic acid synthesis enzyme ALDH1A3 during inner ear development. <i>JCI Insight</i> , 2018, 3, .	2.3	27
35	mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2016, 22, 6129-6141.	3.2	23
36	CHD7 promotes neural progenitor differentiation in embryonic stem cells via altered chromatin accessibility and nascent gene expression. <i>Scientific Reports</i> , 2020, 10, 17445.	1.6	23

#	ARTICLE	IF	CITATIONS
37	Otitis Media in a New Mouse Model for CHARGE Syndrome with a Deletion in the Chd7 Gene. PLoS ONE, 2012, 7, e34944.	1.1	23
38	Mismatch repair-signature mutations activate gene enhancers across human colorectal cancer epigenomes. ELife, 2019, 8, .	2.8	19
39	PRC2 Is Dispensable <i>in Vivo</i> for β -Catenin-Mediated Repression of Chondrogenesis in the Mouse Embryonic Cranial Mesenchyme. G3: Genes, Genomes, Genetics, 2018, 8, 491-503.	0.8	15
40	Targeting Epigenetics to Prevent Obesity Promoted Cancers. Cancer Prevention Research, 2018, 11, 125-128.	0.7	10
41	Chromatin Mechanisms Driving Cancer. Cold Spring Harbor Perspectives in Biology, 2022, 14, a040956.	2.3	9
42	Convergence of case-specific epigenetic alterations identify a confluence of genetic vulnerabilities tied to opioid overdose. Molecular Psychiatry, 2022, 27, 2158-2170.	4.1	9
43	A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs. Stem Cell Reports, 2019, 12, 122-134.	2.3	8
44	Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1077-1089.	1.1	6
45	A Germline Variant on Chromosome 4q31.1 Associates with Susceptibility to Developing Colon Cancer Metastasis. PLoS ONE, 2016, 11, e0146435.	1.1	2
46	PEAR-ing: Genomic and Epigenomic Analyses for Cancer Gene Discovery. Cancer Discovery, 2015, 5, 1018-1020.	7.7	1
47	iPSC Reprogramming Is Not Just an Open and Shut Case. Cell Stem Cell, 2017, 21, 711-712.	5.2	1